Trends in biotech literature 2007 - p1062

Gaspar Taroncher-Oldenburg & Andrew Marshall

doi:10.1038/nbt1008-1062

Full Text - Trends in biotech literature 2007 | PDF (241 KB) - Trends in biotech literature 2007

Where to float? - pp1063 - 1066

Nuala Moran

doi:10.1038/bioe.2008.8

PDF (128 KB) - Where to float?

Ghostbusters should only bust ghosts - pp1067 - 1068

Lanie M Adamson, Mary Whitman, Adam Jacobs & Tracy E Bunting-Early

doi:10.1038/nbt1008-1067

Full Text - Ghostbusters should only bust ghosts | PDF (204 KB) - Ghostbusters should only bust ghosts

Fuelling the 9 billion - pp1068 - 1070

Wayne Martindale & Anthony Trewavas

doi:10.1038/nbt1008-1068

Full Text - Fuelling the 9 billion | PDF (252 KB) - Fuelling the 9 billion

Allergenicity testing of GM crops - pp1070 - 1071

Rob C Aalberse

doi:10.1038/nbt1008-1070

Full Text - Allergenicity testing of GM crops | PDF (175 KB) - Allergenicity testing of GM crops

Reply to Allergenicity testing of GM crops - pp1071 - 1072

doi:10.1038/nbt1008-1071

Full Text - Reply to Allergenicity testing of GM crops | PDF (158 KB) - Reply to Allergenicity testing of GM crops

Field-evolved resistance to Bt toxins - pp1072 - 1074

Willam Moar, Rick Roush, Anthony Shelton, Juan Ferré, Susan MacIntosh, B Rogers Leonard & Craig Abel

doi:10.1038/nbt1008-1072

Full Text - Field-evolved resistance to Bt toxins | PDF (177 KB) - Field-evolved resistance to Bt toxins

Field-evolved resistance to Bt toxins - pp1074 - 1076

doi:10.1038/nbt1008-1074

Full Text - Field-evolved resistance to Bt toxins | PDF (147 KB) - Field-evolved resistance to Bt toxins | Supplementary information

New therapies from old medicines - pp1077 - 1083

Shaw T Chen, Jinhui Dou, Robert Temple, Rajiv Agarwal, Kuei-Meng Wu & Susan Walker

doi:10.1038/nbt1008-1077

Although new botanical drugs pose many challenges for both industry and the FDA, approval of the first botanical prescription drug shows they can be successfully met.

Abstract - | Full Text - New therapies from old medicines | PDF (362 KB) - New therapies from old medicines

A timely marriage - p1084

doi:10.1038/nbt1008-1084

Full Text - A timely marriage | PDF (111 KB) - A timely marriage

A nail in the coffin for DNA sequence patents? - pp1085 - 1086

Miles Yamanaka

doi:10.1038/nbt1008-1085

Does the recent Board decision in Ex parte Kubin mean the end for biotech patents claiming DNA sequences?

Abstract - | Full Text - A nail in the coffin for DNA sequence patents? | PDF (99 KB) - A nail in the coffin for DNA sequence patents?

Recent patent applications in proteomics - p1087

doi:10.1038/nbt1008-1087

Full Text - Recent patent applications in proteomics | PDF (55 KB) - Recent patent applications in proteomics

Next-generation sequencing

Fixing the front end - pp1101 - 1104

Ken Garber

doi:10.1038/nbt1008-1101

One bottleneck in next-generation sequencing is genomic sample selection. As research groups tackle the problem, companies are seizing a market opportunity. Ken Garber reports.

Abstract - | Full Text - Fixing the front end | PDF (163 KB) - Fixing the front end

Next-generation sequencing

What price personal genome exploration? - pp1105 - 1108

Jeffrey L Fox

doi:10.1038/nbt1008-1105

Companies offering direct-to-consumer genomic information face tough questions about who regulates them, where they fit in health care and how to value their services. What will it take to move them from niche services to a broader customer base? Jeffrey Fox reports.

Abstract - | Full Text - What price personal genome exploration? | PDF (390 KB) - What price personal genome exploration?

Next-generation sequencing

The sequencing shakeup - pp1109 - 1112

Amy Coombs

doi:10.1038/nbt1008-1109

Deep sequencing technology could soon be competitive with certain array applications. But the jury remains out on which of the myriad platforms will have the greatest impact and broadest application. Amy Coombs investigates.

Abstract - | Full Text - The sequencing shakeup | PDF (170 KB) - The sequencing shakeup

Next-generation sequencing

How to get genomes at one ten-thousandth the cost - pp1113 - 1115

Jeffery A Schloss

doi:10.1038/nbt1008-1113

The NHGRI's Advanced DNA Sequencing Technology program is spearheading the development of platforms that will bring routine whole-genome sequencing closer to reality.

Abstract - | Full Text - How to get genomes at one ten-thousandth the cost | PDF (350 KB) - How to get genomes at one ten-thousandth the cost

Next-generation sequencing

The development and impact of 454 sequencing - pp1117 - 1124

Jonathan M Rothberg & John H Leamon

doi:10.1038/nbt1485

Abstract - | Full Text - The development and impact of 454 sequencing | PDF (583 KB) - The development and impact of 454 sequencing

Next-generation sequencing

What would you do if you could sequence everything? - pp1125 - 1133

Avak Kahvejian, John Quackenbush & John F Thompson

doi:10.1038/nbt1494

Abstract - | Full Text - What would you do if you could sequence everything? | PDF (908 KB) - What would you do if you could sequence everything?

Next-generation sequencing

Next-generation DNA sequencing - pp1135 - 1145

Jay Shendure & Hanlee Ji

doi:10.1038/nbt1486

Abstract - | Full Text - Next-generation DNA sequencing | PDF (694 KB) - Next-generation DNA sequencing

Next-generation sequencing

The potential and challenges of nanopore sequencing - pp1146 - 1153

Daniel Branton, David W Deamer, Andre Marziali, Hagan Bayley, Steven A Benner, Thomas Butler, Massimiliano Di Ventra, Slaven Garaj, Andrew Hibbs, Xiaohua Huang, Stevan B Jovanovich, Predrag S Krstic, Stuart Lindsay, Xinsheng Sean Ling, Carlos H Mastrangelo, Amit Meller, John S Oliver, Yuriy V Pershin, J Michael Ramsey, Robert Riehn, Gautam V Soni, Vincent Tabard-Cossa, Meni Wanunu, Matthew Wiggin & Jeffery A Schloss

doi:10.1038/nbt.1495

Abstract - | Full Text - The potential and challenges of nanopore sequencing | PDF (1,791 KB) - The potential and challenges of nanopore sequencing

A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology - pp1155 - 1160

Markus J Herrgård, Neil Swainston, Paul Dobson, Warwick B Dunn, K Yalçin Arga, Mikko Arvas, Nils Büthgen, Simon Borger, Roeland Costenoble, Matthias Heinemann, Michael Hucka, Nicolas Le Novère, Peter Li, Wolfram Liebermeister, Monica L Mo, Ana Paula Oliveira, Dina Petranovic, Stephen Pettifer, Evangelos Simeonidis, Kieran Smallbone, Irena Spasié, Dieter Weichart, Roger Brent, David S Broomhead, Hans V Westerhoff, Betül Kürdar, Merja Penttilä, Edda Klipp, Bernhard Ø Palsson, Uwe Sauer, Stephen G Oliver, Pedro Mendes, Jens Nielsen & Douglas B Kell

doi:10.1038/nbt1492

Abstract - | Full Text - A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology | PDF (263 KB) - A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology | Supplementary information

Genome sequencing and analysis of the filamentous fungus Penicillium chrysogenum - pp1161 - 1168

Marco A van den Berg, Richard Albang, Kaj Albermann, Jonathan H Badger, Jean-Marc Daran, Arnold J M Driessen, Carlos Garcia-Estrada, Natalie D Fedorova, Diana M Harris, Wilbert H M Heijne, Vinita Joardar, Jan A K W Kiel, Andriy Kovalchuk, Juan F Martín, William C Nierman, Jeroen G Nijland, Jack T Pronk, Johannes A Roubos, Ida J van der Klei, Noël N M E van Peij, Marten Veenhuis, Hans von Döhren, Christian Wagner, Jennifer Wortman & Roel A L Bovenberg

doi:10.1038/nbt.1498

Penicillins and derived -lactam antibiotics are essential in healthcare. To gain more insight into penicillin synthesis van den Berg and colleagues sequence and analyze the genome and transcriptome of the filamentous fungus Penicillium chrysogenum.

Abstract - | Full Text - Genome sequencing and analysis of the filamentous fungus Penicillium chrysogenum | PDF (487 KB) - Genome sequencing and analysis of the filamentous fungus Penicillium chrysogenum | Supplementary information

Notch signaling respecifies the hemangioblast to a cardiac fate - pp1169 - 1178

Vincent C Chen, Robert Stull, Daniel Joo, Xin Cheng & Gordon Keller

doi:10.1038/nbt.1497

The development of effective methods for generating cardiomyocytes from embryonic stem cells may prove useful in cell replacement therapies and drug screening. Chen et al. show that activation of Notch signaling efficiently converts hematopoietic progenitors derived from mouse embryonic stem cells into cardiovascular progenitors that give rise to large numbers of cardiomyocytes.

Abstract - | Full Text - Notch signaling respecifies the hemangioblast to a cardiac fate | PDF (676 KB) - Notch signaling respecifies the hemangioblast to a cardiac fate | Supplementary information

Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy - pp1179 - 1186

Joshua Munger, Bryson D Bennett, Anuraag Parikh, Xiao-Jiang Feng, Jessica McArdle, Herschel A Rabitz, Thomas Shenk & Joshua D Rabinowitz

doi:10.1038/nbt.1500

Munger et al. show that infection with human cytomegalovirus upregulates fatty acid biosynthesis and that pharmacological inhibition of this pathway inhibits replication of both this virus and influenza A. This approach, the first to reliably map major carbon fluxes in mammalian cells, extends the promise of metabolomics from diagnostic applications to identification of new therapeutic concepts.

Abstract - | Full Text - Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy | PDF (463 KB) - Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy | Supplementary information

See also: News and Views by Sauer & Zamboni

Small-molecule inhibition of HIV-1 Vif - pp1187 - 1192

Robin Nathans, Hong Cao, Natalia Sharova, Akbar Ali, Mark Sharkey, Ruzena Stranska, Mario Stevenson & Tariq M Rana

doi:10.1038/nbt.1496

The HIV-1 protein Vif, which promotes degradation of the host cell's antiviral APOBEC3 proteins, has yet to be targeted for therapeutic intervention. Nathans et al. use a high-throughput fluorescence screen to identify a small molecule that inhibits HIV replication in cultured cells by antagonizing Vif in an APOBEC3-dependent manner.

First Paragraph - | Full Text - Small-molecule inhibition of HIV-1 Vif | PDF (431 KB) - Small-molecule inhibition of HIV-1 Vif | Supplementary information

See also: News and Views by Harris

Corrigendum: Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina) - p1193

Diego Martinez, Randy M Berka, Bernard Henrissat, Markku Saloheimo, Mikko Arvas, Scott E Baker, Jarod Chapman, Olga Chertkov, Pedro M Coutinho, Dan Cullen, Etienne G J Danchin, Igor V Grigoriev, Paul Harris, Melissa Jackson, Christian P Kubicek, Cliff S Han, Isaac Ho, Luis F Larrondo, Alfredo Lopez de Leon, Jon K Magnuson, Sandy Merino, Monica Misra, Beth Nelson, Nicholas Putnam, Barbara Robbertse, Asaf A Salamov, Monika Schmoll, Astrid Terry, Nina Thayer, Ann Westerholm-Parvinen, Conrad L Schoch, Jian Yao, Ravi Barabote, Mary Anne Nelson, Chris Detter, David Bruce, Cheryl R Kuske, Gary Xie, Paul Richardson, Daniel S Rokhsar, Susan M Lucas, Edward M Rubin, Nigel Dunn-Coleman, Michael Ward & Thomas S Brettin

doi:10.1038/nbt1008-1193a

Full Text - Corrigendum: Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina) | PDF (67 KB) - Corrigendum: Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina)

Corrigendum: Public biotech 2007—the numbers - p1193

Stacy Lawrence & Riku Lähteenmäki

doi:10.1038/nbt1008-1193b

Full Text - Corrigendum: Public biotech 2007—the numbers | PDF (67 KB) - Corrigendum: Public biotech 2007—the numbers

Corrigendum: Predicting PDZ domain–peptide interactions from primary sequences - p1193

Jiunn R Chen, Bryan H Chang, John E Allen, Michael A Stiffler & Gavin MacBeath

doi:10.1038/nbt1008-1193c

Full Text - Corrigendum: Predicting PDZ domain–peptide interactions from primary sequences | PDF (67 KB) - Corrigendum: Predicting PDZ domain–peptide interactions from primary sequences

So you want to be a venture capitalist? - pp1195 - 1196

Jason Brown

doi:10.1038/nbt1008-1195

Venture capitalists have a key role in the translation of scientific innovation from idea to commercial reality.

Abstract - | Full Text - So you want to be a venture capitalist? | PDF (118 KB) - So you want to be a venture capitalist?

People - p1198

doi:10.1038/nbt1008-1198

Full Text - People | PDF (104 KB) - People